Brief: Bergenbio Q2 Operating Expenses at NOK 47.8 Million
23/08/2023 06:07
Aug 23 (Reuters) - Bergenbio Q2 operating expenses NOK 47.8 million. * Q2 revenue NOK 0
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee